TY - JOUR
T1 - Methylphenidate and Sleep Difficulties in Children and Adolescents With ADHD
T2 - Results From the 2-Year Naturalistic Pharmacovigilance ADDUCE Study
AU - Häge, Alexander
AU - Man, Kenneth K.C.
AU - Inglis, Sarah K.
AU - Buitelaar, Jan
AU - Carucci, Sara
AU - Danckaerts, Marina
AU - Dittmann, Ralf W.
AU - Falissard, Bruno
AU - Garas, Peter
AU - Hollis, Chris
AU - Konrad, Kerstin
AU - Kovshoff, Hanna
AU - Liddle, Elizabeth
AU - McCarthy, Suzanne
AU - Neubert, Antje
AU - Nagy, Peter
AU - Rosenthal, Eric
AU - Sonuga-Barke, Edmund J.S.
AU - Zuddas, Alessandro
AU - Wong, Ian C.K.
AU - Coghill, David
AU - Banaschewski, Tobias
PY - 2024/3
Y1 - 2024/3
N2 - Objective: Short-term RCTs have demonstrated that MPH-treatment significantly reduces ADHD-symptoms, but is also associated with adverse events, including sleep problems. However, data on long-term effects of MPH on sleep remain limited. Methods: We performed a 2-year naturalistic prospective pharmacovigilance multicentre study. Participants were recruited into three groups: ADHD patients intending to start MPH-treatment (MPH-group), those not intending to use ADHD-medication (no-MPH-group), and a non-ADHD control-group. Sleep problems were assessed with the Children’s-Sleep-Habits-Questionnaire (CSHQ). Results: 1,410 participants were enrolled. Baseline mean CSHQ-total-sleep-scores could be considered clinically significant for the MPH-group and the no-MPH-group, but not for controls. The only group to show a significant increase in any aspect of sleep from baseline to 24-months was the control-group. Comparing the MPH- to the no-MPH-group no differences in total-sleep-score changes were found. Conclusion: Our findings support that sleep-problems are common in ADHD, but don’t suggest significant negative long-term effects of MPH on sleep.
AB - Objective: Short-term RCTs have demonstrated that MPH-treatment significantly reduces ADHD-symptoms, but is also associated with adverse events, including sleep problems. However, data on long-term effects of MPH on sleep remain limited. Methods: We performed a 2-year naturalistic prospective pharmacovigilance multicentre study. Participants were recruited into three groups: ADHD patients intending to start MPH-treatment (MPH-group), those not intending to use ADHD-medication (no-MPH-group), and a non-ADHD control-group. Sleep problems were assessed with the Children’s-Sleep-Habits-Questionnaire (CSHQ). Results: 1,410 participants were enrolled. Baseline mean CSHQ-total-sleep-scores could be considered clinically significant for the MPH-group and the no-MPH-group, but not for controls. The only group to show a significant increase in any aspect of sleep from baseline to 24-months was the control-group. Comparing the MPH- to the no-MPH-group no differences in total-sleep-score changes were found. Conclusion: Our findings support that sleep-problems are common in ADHD, but don’t suggest significant negative long-term effects of MPH on sleep.
KW - ADHD
KW - long-term safety
KW - methylphenidate
KW - pharmacovigilance
KW - sleep problems
UR - https://journals.sagepub.com/doi/10.1177/10870547241232337
UR - http://www.scopus.com/inward/record.url?scp=85186392143&partnerID=8YFLogxK
U2 - 10.1177/10870547241232337
DO - 10.1177/10870547241232337
M3 - Article
C2 - 38389266
AN - SCOPUS:85186392143
SN - 1087-0547
VL - 28
SP - 699
EP - 707
JO - Journal of attention disorders
JF - Journal of attention disorders
IS - 5
ER -